Physician profile
Marijane Tinoco
NPI 1295487411
$2,088.56
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $312 · 2023: $1,311 · 2024: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.89 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $634.98 | 2023-2024 | Sotyktu |
| Incyte Corporation | $467.47 | 2022-2024 | Opzelura |
| Genzyme Corporation | $260.23 | 2023-2024 | |
| Leo Pharma INC. | $165.04 | 2022-2023 | Adbry |
| Abbvie INC. | $128.51 | 2023 | |
| Pfizer INC. | $85.37 | 2022-2023 | |
| Verrica Pharmaceuticals INC. | $71.57 | 2023-2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $59.99 | 2024 | |
| Paratek Pharmaceuticals, INC. | $57.58 | 2023 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $43.18 | 2023-2024 | Dupixent |
| Organogenesis INC. | $41.15 | 2023 | Puraply |
| Amgen INC. | $25.58 | 2022 | |
| Fresenius Kabi USA, LLC | $25.19 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $22.72 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marijane Tinoco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.